| scholarly article | Q13442814 |
| P2093 | author name string | Richard Rauck | |
| Marvin Tark | |||
| Lynn R. Webster | |||
| Geertrui F. Vanhove | |||
| Jeffrey K. Tobias | |||
| P2860 | cites work | Treatment of herpes zoster and postherpetic neuralgia | Q24527247 |
| Pain assessment: global use of the Brief Pain Inventory | Q28247739 | ||
| Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? | Q28265537 | ||
| Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course | Q28325434 | ||
| Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies | Q33255110 | ||
| Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. | Q33332025 | ||
| Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. | Q33777417 | ||
| Zoster-associated pain and neural dysfunction | Q34282274 | ||
| Pharmacologic management of neuropathic pain: evidence-based recommendations | Q34699259 | ||
| Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy | Q35004161 | ||
| Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies | Q35925582 | ||
| Algorithm for neuropathic pain treatment: an evidence based proposal. | Q36280904 | ||
| Rational multidrug therapy in the treatment of neuropathic pain | Q36405671 | ||
| Pharmacotherapy for neuropathic pain | Q36739954 | ||
| NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain | Q39301276 | ||
| NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study | Q39312497 | ||
| Topical capsaicin treatment of chronic postherpetic neuralgia. | Q39523524 | ||
| Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale | Q40678235 | ||
| Postherpetic neuralgia--pathogenesis, treatment, and prevention | Q40990582 | ||
| NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension | Q43180409 | ||
| ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions | Q46548884 | ||
| Prevention and treatment of postherpetic neuralgia | Q46904622 | ||
| A Multicenter, Randomized, Double-Blind, Controlled Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia | Q50440477 | ||
| A new treatment for postherpetic neuralgia. | Q51372417 | ||
| Capsaicin evoked pain and allodynia in post-herpetic neuralgia | Q60684292 | ||
| The short-form McGill Pain Questionnaire | Q69431032 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 92 | |
| P577 | publication date | 2010-10-11 | |
| P1433 | published in | BMC Neurology | Q15763734 |
| P1476 | title | Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia | |
| P478 | volume | 10 |
| Q34301601 | A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial |
| Q44735809 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia |
| Q36350737 | Current challenges in translational pain research |
| Q86606554 | Local Therapies for Localised Neuropathic Pain |
| Q39191235 | Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. |
| Q28079910 | Profile of the capsaicin 8% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability |
| Q37820983 | Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia |
| Q38201876 | Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions |
| Q39001059 | The Effectiveness and Safety of Topical Capsaicin in Postherpetic Neuralgia: A Systematic Review and Meta-analysis |
| Q37295147 | The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis |
| Q38125487 | Therapeutic options for the treatment of postherpetic neuralgia: a systematic review |
| Q40324493 | Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain |
| Q34376548 | Topical analgesics for neuropathic pain: preclinical exploration, clinical validation, future development |
| Q24200709 | Topical capsaicin (high concentration) for chronic neuropathic pain in adults |
| Q34549233 | Topical capsaicin (high concentration) for chronic neuropathic pain in adults. |
| Q38221259 | Topical capsaicin formulations in the management of neuropathic pain. |
| Q37997774 | Transdermal patches for the treatment of neurologic conditions in elderly patients: a review |
Search more.